Accelerate Bio Podcast $100 Trillion Future of Biotech: AI, China & Next Industrial Revolution | Jason Kelly, Ginkgo CEO
6 snips
Nov 13, 2025 
Jason Kelly, CEO of Ginkgo Bioworks and pioneer in industrializing biology, discusses the future of biotech with cutting-edge insights. He argues that AI and lab automation will redefine science, making biology akin to software. Kelly highlights challenges in programming biology and the need for splitting lab work from design. He explores the impact of regulations, the burgeoning field of human enhancement, and how China's advancements could reshape the industry. Join him in envisioning a future where machines and AI drive scientific discovery.
AI Snips
Chapters
Transcript
Episode notes
Split Lab Work From Design
- Abstraction, not brute-force lab skills, is the missing layer that will let many more people program biology.
- Jason Kelly argues we must split lab execution (automation) from genomic design to democratize biotech.
Consumer SynBio Struggled To Scale
- Non-therapeutic synthetic biology has largely failed to produce blockbuster consumer wins so far.
- Jason notes many consumer SynBio companies struggled after funding tightened and markets didn't scale.
Monitor Human Enhancements Closely
- Pursue consumer-facing human enhancement and monitored interventions cautiously, with strong safety tracking.
- Use frequent biomarker monitoring to manage risk and enable responsible innovation.